Intelligent Fingerprinting, the Cambridge-based company developing the world’s first portable fingerprint-based drug screening system, has appointed Martin Payne as Director of Quality to head up the company’s Quality Assurance and Regulatory Affairs activities.
Martin Payne brings more than 20 years’ senior Quality Assurance and Regulatory Affairs experience to his role at Intelligent Fingerprinting.
Martin’s appointment coincides with the company’s moving towards the commercialisation of its unique, non-invasive drug screening system.
US Food & Drug Administration (FDA) approval will enable the targeting of workplace and healthcare applications.
Payne said: “I’m looking forward to supporting the company’s preparations for FDA and making sure that we have all the right activities and processes in place to support subsequent intended uses of our drug screening system.”
At Philips Electronics, Martin spent six years as Director of Quality Assurance, Regulatory Affairs and Clinical and Medical Affairs for the company’s Home Clinical Monitoring operation.
In this role, he was focused particularly on the development of clinical monitoring activities for patients self-testing at home.
This experience is particularly relevant for future Intelligent Fingerprinting applications, such as the monitoring of drug use via home-based tests.
Jerry Walker, Intelligent Fingerprinting’s CEO, added: “Quality informs everything we do at Intelligent Fingerprinting, so I’m delighted that we have been able to bring a senior Quality Assurance and Regulatory Affairs leader on board to help support us in achieving our FDA approval.”
“Martin is an important addition to our management team as we move towards commercialisation.”
